Serbian tennis player Novak Djokovic arrives at Nikola Tesla Airport, after the Australian Federal Court upheld a government decision to cancel his visa to play in the Australian Open, in Belgrade, Serbia January 17, 2022. REUTERS/Christopher Pike
COPENHAGEN (Reuters) - The pandemic has blocked Novak Djokovic's march to tennis history, so the 34-year-old may be pinning his hopes on a cure for COVID to get his hands on another glorious grand slam before time runs out.
The Serbian superstar, who became a focus of the global vaccine debate over his failed attempt to enter Australia without being inoculated, holds a majority stake in a Danish biotech firm aiming to develop a treatment to counter COVID-19, the company's CEO told Reuters.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
